Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-09-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于股东股份解除冻结的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the解除冻结 (unfreezing) of shares held by a specific shareholder, 林长青, including details about the number of shares unfrozen and the impact on shareholding percentages. It references previous announcements about judicial freezing but does not contain financial statements, management discussion, or detailed financial data. The document is under 5,000 characters and serves as a regulatory disclosure about share status changes rather than a full report or detailed financial filing. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2024-09-27 Chinese
美迪西：关于参加2024年半年度科创板制药及生物制品专场集体业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in a 2024 semi-annual performance explanation meeting organized by the Shanghai Stock Exchange. It details the meeting's date, format (online text interaction), participants, and how investors can submit questions. It references the company's 2024 semi-annual report already disclosed on August 20, 2024, but this document itself is not the report or a transcript of the meeting. It is a notice about the upcoming investor presentation event focused on financial results and business updates. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the actual report or transcript.
2024-09-06 Chinese
美迪西：关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It does not contain financial statements or analysis but reports on the status of the share buyback activity. The document length is short (1517 characters) and focuses on the repurchase progress rather than a full financial report or earnings release. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers announcements of share buybacks or sales by the company.
2024-09-02 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2024年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024 年半年度持续督导跟踪报告" (2024 Semi-Annual Continuous Supervision Follow-up Report) issued by the sponsor (广发证券股份有限公司) for the company 上海美迪西生物医药股份有限公司. It references regulatory frameworks related to securities issuance and listing supervision, and contains detailed information about the sponsor's ongoing supervision activities, risk factors, financial data for the half-year period ending June 2024, compliance with fundraising usage, shareholding and pledging status of directors and senior management, and other governance and operational matters. The document is comprehensive and contains substantive financial data and analysis for a half-year period, consistent with an Interim / Quarterly Report. It is not a full Annual Report (10-K), nor is it a brief announcement or certification. It is not a call transcript, proxy statement, or other categories. The document length (9979 characters) and content confirm it is a detailed half-year report with financial and operational information. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2024
2024-09-02 Chinese
美迪西：2024年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by Shanghai Medicilon Inc. during the first half of 2024. It includes specifics on the amount raised, usage, bank accounts, investment projects, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and it is titled as a "special report on the storage and use of raised funds for the half-year 2024." It contains substantive financial data and analysis related to fundraising and capital usage, not just an announcement or certification. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 6,000 characters and contains detailed financial and operational data about the fundraising and use of proceeds, so it is not a mere announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2024-08-19 Chinese
美迪西：2024年度“提质增效重回报”行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '半年度评估报告' which translates to 'Half-Year Assessment Report' for the year 2024. It provides detailed operational, financial, and strategic updates for the first half of 2024, including revenue figures, R&D progress, governance improvements, investor communications, and share repurchase activities. The content includes substantive financial data and business analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. The document length is 4311 characters, which is sufficient to contain detailed information rather than just an announcement. There is no indication that this is merely a publication announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-19 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.